Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 24:18:3117-3139.
doi: 10.2147/JPR.S521788. eCollection 2025.

Consensus Guidelines from the American Society of Pain and Neuroscience for the Use of 60-Day Peripheral Nerve Stimulation Therapy. A NEURON Living Guideline Project

Affiliations

Consensus Guidelines from the American Society of Pain and Neuroscience for the Use of 60-Day Peripheral Nerve Stimulation Therapy. A NEURON Living Guideline Project

Benjamin Gill et al. J Pain Res. .

Abstract

Peripheral nerve stimulation (PNS) has evolved with various applications and durations of therapy. In recent years, extensive data has been developed on a 60-day treatment using a novel approach. Confusion exists on the use of a trial therapy, a permanent implant, and a 60-day duration treatment. The American Society of Pain and Neuroscience (ASPN) seeks to clarify the literature associated with this neuromodulation approach. A diverse group of experts was nominated to provide opinions and guidance based on evidence-graded assessment and clinical knowledge. This guidance is the first to specifically assess the clinical use of 60-day PNS and best medical practice.

Keywords: best practices; clinical guidelines; pain medicine; peripheral nerve stimulation.

PubMed Disclaimer

Conflict of interest statement

Usman Latif: Consultant: Abbott, Brixton Biosciences, Hydrocision, Nalu Medical, Nevro, Omnia Medical, Saluda, Spinal Simplicity, SPR Therapeutics, Stryker, Vertos Medical, Vivex Biologics; Research funding: Mainstay Medical, Spinal Simplicity, Vivex Biologics; Stock: InFormed Consent, Spinal Simplicity. Scott Pritzlaff: Consultant SPR Therapeutics, Bioventus, Nalu Medical; Education grants from Abbott, Biotronik, Medtronic, and Nevro; Royalties from Wolters Kluwer. Ioannis Skaribas: Consultant Abbott, Nalu. Hemant Kalia: Consultant Abbott, Averitas, Nalu, Curonix, SPR Therapeutics, Nervonik, Virdio Health. Samir Sheth: Consultant SPR, Medtronic, Vertos, Boston Scientific, SI Bone; Royalties from Wolters Kluwer. Madi Schnur: Consultant SPR Therapeutics. Sean Li: Consultant Abbott, Avanos, Averitas Pharma, Boston Scientific, Biotronik, Medtronic, Nalu Medical, PainTeq, Presidio, Saluda, SPR Therapeutics, Stryker; Research funding Avanos, Averitas Pharma, Nevro, Presidio, SPR Therapeutics, Stock options NeuroOne, Nalu Medical. Denise Lester: the Primary Investigator for the RESET trial; Research funding from SPR Therapeutics. Ramana Naidu: Consultant Abbott, Avanos, Boston Scientific, Bioventus, Biotronik, Medtronic, Nalu Medical, Nervonik, SPR Therapeutics. Royalties from McGraw-Hill. David Russo: Consultant Nalu, Nevro. Einar Ottestad: Consultant for BioVentus, SPR Therapeutics, Coloplast; Stock options for Restera Medical; Co-founder Altamont Medical. Henry Vucetic: Consultant Abbott, SPR Therapeutics, Vertos, Saluda, Boston Scientific. David Abejón: Proctor Abbott, Medtronic, Boston Scientific, Cardiva, MBA, Saluda Medical. Mehul Desai: Consultant Medtronic, Nalu Medical Stock Options AllaiHealth, HypreVention, SPR Therapeutics, SynerFuse, Virdio Health, Royalties Oxford Medical. David Dickerson: Consultant SPR, Stryker, Nalu, Vertos, Vertex, Abbott, Biotronik; Research support Abbott, SPR. Amitabh Gulati: Consultant for SPR therapeutics, Nalu Medical, Medtronic, AIS healthcare, Neurovasis, Tersera Medical, Hinge Health, Menda Health, Veritas Pharma. Sayed Dawood: Stock Options Spr, Painteq, Mainstay; personal fees from Abbott, Saluda. Timothy Deer: consultant research Abbott, SpineThera, Saluda Medical, Cornerloc, Boston Scientific, personal fees, Pain Teq, Spinal Simplicity, Biotronik, Aurora, Nervonik, SPR Therapeutics, outside the submitted work; In addition, Dr Timothy Deer has a patent pending to Abbott. The other authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Responder Rates from Initiation of PNS Treatment. Reprinted with permission from Dove Medical Press. Naidu R, Li S, Desai MJ, Sheth S, Crosby ND, Boggs JW. 60-Day PNS Treatment May Improve Identification of Delayed Responders and Delayed Non-Responders to Neurostimulation for Pain Relief. Journal of Pain Research. 2022;15:733–743.
Figure 2
Figure 2
Pain Response to PNS in Post-Amputation Pain. Reprinted from Gilmore CA, Ilfeld BM, Rosenow JM et al. Percutaneous 60-day peripheral nerve stimulation implant provides sustained relief of chronic pain following amputation: 12-month follow-up of a randomized, double-blind, placebo-controlled trial. Regional Anesthesia & Pain Medicine. 2020;45(1):44–51. Creative Commons.

Similar articles

References

    1. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150(3699):971–979. doi: 10.1126/science.150.3699.971 - DOI - PubMed
    1. Wall PD, Sweet WH. Temporary abolition of pain in man. Science. 1967;155(3758):108–109. doi: 10.1126/science.155.3758.108 - DOI - PubMed
    1. Deer TR, Levy RM, Verrills P, Mackey S, Abejon D. Perspective: peripheral nerve stimulation and peripheral nerve field stimulation birds of a different feather. Pain Med. 2015;16(3):411–412. doi: 10.1111/pme.12662 - DOI - PubMed
    1. Strand N, D’Souza RS, Hagedorn JM, et al. Evidence-based clinical guidelines from the American society of pain and neuroscience for the use of implantable peripheral nerve stimulation in the treatment of chronic pain. J Pain Res. 2022;15:2483–2504. doi: 10.2147/JPR.S362204 - DOI - PMC - PubMed
    1. Gildenberg PL. History of electrical neuromodulation for chronic pain. Pain Med. 2006;7(s1):S7–S13.

LinkOut - more resources